Sana Biotechnology saw the highest growth of 1.79% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.79% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Sana Biotechnology’s patent filings and grants. Buy the databook here.
Sana Biotechnology has been focused on protecting inventions in European Patent Office(EPO) with 11 publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 41% of filings. The European Patent Office(EPO), World Intellectual Property Organization(WIPO), South Korea(KR), and Israel(IL) patent Office are among the top ten patent offices where Sana Biotechnology is filings its patents. Among the top granted patent authorities, Sana Biotechnology has 100% of its grants in United States(US).
Immatics and University of Pennsylvania could be the strongest competitors for Sana Biotechnology
Patents related to cell & gene therapy and machine learning lead Sana Biotechnology's portfolio
Sana Biotechnology has the highest number of patents in cell & gene therapy followed by, machine learning. For cell & gene therapy, nearly 62% of patents were filed and 100% of patents were granted in Q2 2024.
Cell therapy related patents lead Sana Biotechnology portfolio followed by oral mucositis, and diabetes
Sana Biotechnology has highest number of patents in cell therapy followed by oral mucositis, diabetes.
For comprehensive analysis of Sana Biotechnology's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.